STOCK TITAN

AC Immune SA (ACIU) SEC Filings, Jan-Mar 2026

ACIU NASDAQ

AC Immune SA filings document a foreign private issuer developing precision therapeutics and diagnostics for neurodegenerative diseases. Recent Form 6-K reports furnish press releases, IFRS financial statements, management discussion and annual statutory and compensation reports, with certain reports incorporated by reference into Form F-3 and Form S-8 registration statements.

The disclosures cover clinical and trial updates for ACI-24, ACI-7104.056, ACI-19764 and ACI-35.030/JNJ-2056; collaboration amendments for Morphomer® Tau small molecules; cash resources and operating requirements; and governance-related compensation reporting. They also record exhibit-based material updates for AC Immune’s active immunotherapy, small-molecule and diagnostic pipeline.

Rhea-AI Summary

AC Immune SA director Monika Buetler filed an initial statement of beneficial ownership, detailing existing share and option positions. She reports direct ownership of 53,905 common shares, which includes 52,905 common shares underlying outstanding restricted share units. This filing does not show new buying or selling activity.

Buetler also holds several share options over AC Immune common shares with different exercise prices and maturities. These include options over 14,310 shares at an exercise price of 5.3100 that are fully vested and expire on December 9, 2031, and options over 56,204 shares at an exercise price of 3.1500 expiring on June 23, 2032. She further holds options over 39,823 shares at 2.1500 expiring June 23, 2033, and 15,501 shares at 4.2300 expiring June 30, 2034. Another option covers 46,392 shares at 1.8400 and will fully vest on June 17, 2026, with expiration on June 17, 2035. Together, these positions describe her current equity-based exposure to AC Immune, rather than recent market transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
insider
-
Rhea-AI Summary

AC Immune SA director Roy Ervin Twyman reported his initial holdings on a Form 3. He directly holds 75,988 common shares, including 49,988 common shares underlying outstanding restricted share units. He also holds multiple share options over common shares with exercise prices between $1.84 and $7.23, expiring from 2029 through 2035.

According to the footnotes, at least one share option grant is fully vested and another will fully vest on June 17, 2026, highlighting a mix of already exercisable and time-based equity awards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
insider
-
Rhea-AI Summary

AC Immune SA director Renee Aguiar‑Lucander has filed an initial ownership report. The filing shows direct ownership of 34,568 Common Shares. She also holds two share option awards, each exercisable at $1.8400 per share and expiring on June 17, 2035, covering 43,299 and 32,061 underlying Common Shares.

According to the footnotes, the 43,299-share option will fully vest on June 17, 2026, while the 32,061-share option vests in three equal annual installments beginning on that same date. This Form 3 records her starting equity position as a director rather than reporting new market transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
insider
Rhea-AI Summary

AC Immune SA Chief Executive Officer Andrea Pfeifer filed an initial statement of beneficial ownership, reporting 3,840,288 Common Shares held directly and 14,000 Common Shares held indirectly by her spouse. The direct position includes 1,921,005 Common Shares underlying outstanding restricted share units.

The filing also lists several fully vested share options over Common Shares with exercise prices between 2.03 and 9.53 per share and expiration dates from 2027 through 2032, providing a detailed snapshot of the CEO’s current equity-based incentives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
insider
-
Rhea-AI Summary

AC Immune SA director June Carl Howard has filed an initial ownership report showing equity interests in the company. Howard directly holds 50,988 common shares, including 49,988 common shares underlying outstanding restricted share units. In addition, Howard holds several fully vested or time‑vesting share options to purchase common shares at exercise prices ranging from $1.84 to $7.23, with expiration dates between 2030 and 2035. This filing records existing positions and does not reflect any new share purchases or sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
insider
-
Rhea-AI Summary

AC Immune reported full-year 2025 results, highlighting pipeline progress alongside a wider loss. Contract revenue fell to CHF 3.6m from CHF 27.3m, mainly as prior Janssen milestones rolled off, while the net loss widened to CHF 70.4m with a basic and diluted loss per share of CHF 0.70.

Cash and cash equivalents were CHF 26.8m and short-term financial assets CHF 64.6m as of December 31, 2025, and management prepared the accounts on a going-concern basis. The company emphasized positive interim VacSYn Phase 2 data for ACI-7104 in early Parkinson’s disease, a Phase 1 NLRP3 inhibitor (ACI-19764), and a sharpened pipeline focus supported by 2025 restructuring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.50%
Tags
current report
Rhea-AI Summary

AC Immune is a Switzerland-based biopharmaceutical company focused on therapies and diagnostics for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. It has no approved products and does not expect product revenue for several years, relying instead on R&D collaborations and funding.

The pipeline includes active immunotherapies ACI‑35.030, ACI‑24.060 and ACI‑7104.056, small molecule ACI‑19764 and Morphomer programs, and PET tracers PI‑2620, ACI‑12589, ACI‑15916 and ACI‑19626. Several assets have FDA Fast Track designation. Key partners include Eli Lilly, Janssen, Lantheus and Takeda.

The filing emphasizes extensive risks: clinical failure or delay, heavy dependence on partners, intense competition, IP and generic challenges, reimbursement pressures, ESG and climate rules, cybersecurity and data‑privacy exposure, pandemics, geopolitical shocks and new U.S. trade tariffs. As of the period end, 101,742,231 common shares were outstanding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.50%
Tags
annual report
-
Rhea-AI Summary

AC Immune SA has begun a Phase 1 clinical trial of ACI-19764, an orally administered small molecule that inhibits the NLRP3 inflammasome. The first healthy volunteer has been dosed, marking the program’s entry into human testing.

The Europe-based study will evaluate single and multiple ascending doses to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, including drug levels in plasma and cerebrospinal fluid and inhibition of IL-1β as a measure of target engagement. Initial data are expected in the second half of 2026.

Preclinical data suggest ACI-19764 is highly brain penetrant and potent, with strong effects on neuroinflammation and weight control in animal models, supporting its potential in metabolic and neurological diseases such as Alzheimer’s, Parkinson’s, ALS and frontotemporal dementia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.51%
Tags
current report
-
Rhea-AI Summary

AC Immune reported that partner Janssen has temporarily paused enrollment in the Phase 2b ReTain study of ACI-35.030/JNJ-2056 in preclinical Alzheimer’s disease while it evaluates aspects of the trial, including recruitment. The company states this voluntary pause is not due to new safety findings and that the trial’s pre-specified interim immunogenicity threshold was met.

The company says this pause does not affect its liquidity and that existing capital resources are expected to fund operations into Q3 2027, excluding any potential milestone payments. In 2026, AC Immune anticipates multiple clinical readouts from its active immunotherapy programs in Alzheimer’s and Parkinson’s disease and expects its ACI-19764 Phase 1 trial in healthy volunteers to start dosing imminently, with results anticipated in the second half of 2026. AC Immune also plans to report Q4 2025 earnings on March 12.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.97%
Tags
current report
Rhea-AI Summary

A planned insider sale of common stock has been disclosed under Rule 144. The person named in the notice, Andrea Pfeifer, plans to sell 30,000 shares of common stock through Morgan Stanley Smith Barney LLC on or around 01/15/2026, with an indicated aggregate market value of $110,100.00. The filing notes that 100,600,000 shares of this class are outstanding and lists NASDAQ as the securities exchange.

The shares to be sold were originally acquired on 06/01/2012 by exercising stock options issued by the company and paid for in cash. Over the past three months, there was a separate 10b5-1 sale for Andrea Pfeifer of 500 common shares on 10/29/2025 for gross proceeds of $2,000.00. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
other

FAQ

How many AC Immune SA (ACIU) SEC filings are available on StockTitan?

StockTitan tracks 47 SEC filings for AC Immune SA (ACIU), including 20-F annual reports and 6-K reports. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for AC Immune SA (ACIU)?

The most recent SEC filing for AC Immune SA (ACIU) was filed on November 4, 2026.